Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Brainstorm Cell Therapeutics ( (BCLI) ) has provided an update.
On July 16, 2025, BrainStorm Cell Therapeutics Inc. was notified by Nasdaq of its decision to delist the company’s common stock due to non-compliance with Nasdaq’s minimum shareholder equity requirement. Consequently, trading on Nasdaq will be suspended on July 18, 2025. The company has secured approval for its stock to be quoted on the OTCQB Venture Market, ensuring continuous trading under the symbol BCLI. This transition does not impact BrainStorm’s business operations or its commitment to advancing its NurOwn therapy for ALS patients, as stated by CEO Chaim Lebovits.
The most recent analyst rating on (BCLI) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Brainstorm Cell Therapeutics stock, see the BCLI Stock Forecast page.
Spark’s Take on BCLI Stock
According to Spark, TipRanks’ AI Analyst, BCLI is a Underperform.
Brainstorm Cell Therapeutics’ stock score is significantly impacted by its financial performance challenges, including ongoing losses and negative cash flows. While there are strategic advancements and partnerships aimed at derisking the regulatory pathway, the company’s valuation and technical indicators reflect a bearish outlook. Investors should be cautious due to financial constraints and skepticism regarding the efficacy of its lead treatment, NurOwn.
To see Spark’s full report on BCLI stock, click here.
More about Brainstorm Cell Therapeutics
BrainStorm Cell Therapeutics Inc. is a leading developer of autologous adult stem cell therapies for neurodegenerative diseases. The company’s proprietary NurOwn® platform uses autologous mesenchymal stem cells to produce neurotrophic factor-secreting cells, designed to modulate neuroinflammation and promote neuroprotection. NurOwn® is the lead investigational therapy for amyotrophic lateral sclerosis (ALS) and has received Orphan Drug designation from the FDA and EMA.
Average Trading Volume: 1,370,701
Technical Sentiment Signal: Sell
Current Market Cap: $11.81M
For detailed information about BCLI stock, go to TipRanks’ Stock Analysis page.